Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials

Efficacy and safety of B/F/TAF in treatment-naïve and virologically suppressed people with HIV ≥ 50 years of age: integrated analysis from six phase 3 clinical trials

Abstract Introduction Older adults with HIV, particularly those ≥ 50 years of age, face unique health challenges due to a higher prevalence of comorbidities and polypharmacy, which can impact medication adherence and increase the risk of adverse events. We assessed the efficacy and safety of bictegr...

Full description

Saved in:
Bibliographic Details
Main Authors: Cissy M. Kityo, Samir K. Gupta, Princy N. Kumar, Amy R. Weinberg, Bhumi Gandhi-Patel, Hui Liu, Jason T. Hindman, Jürgen K. Rockstroh
Format: Article
Language:English
Published: BMC 2025-08-01
Series:BMC Infectious Diseases
Subjects:
HIV
Older adults
B/F/TAF
Antiretroviral therapy
Comorbidities
Online Access:https://doi.org/10.1186/s12879-025-11476-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12879-025-11476-3

Similar Items